Methods and Compositions for the Treatment of Pancreatic Cancer
AssigneeOpsona Therapeutics Limited
InventorThorsten Hagemann
Life of this patent
Estimating the term…
Abstract
A composition comprising a TLR2 antagonistic antibody or antigen binding fragment thereof for use in the treatment or prophylaxis of pancreatic cancer is provided. The antibody or antigen binding fragment may be provided for simultaneous, separate or sequential administration with a secondary chemotherapeutic agent such as gemcitabine, and optionally a tertiary chemotherapeutic agent such as abraxane for enhanced treatment. Also provided is a screening method for the identification of compounds for use in treatment or prevention of pancreatic cancer.
Claims32
1-22. (canceled)
A method for treating or preventing pancreatic cancer comprising the step of:
- administering a therapeutically effective amount of a Toll-like receptor 2 (TLR2) antagonist to a subject in need thereof wherein the TLR2 antagonist is an antibody that specifically binds to TLR2, or an antigen binding fragment thereof.
(canceled)
43-66. (canceled)
A pharmaceutical composition comprising a TLR2 antagonistic antibody or an antigen binding fragment thereof, a pharmaceutically acceptable carrier, a secondary chemotherapeutic agent that increases TLR2 expression when administered without a TLR2 antagonist and abraxane.
A pharmaceutical composition comprising a TLR2 antagonistic antibody or an antigen binding fragment thereof, a pharmaceutically acceptable carrier and a secondary chemotherapeutic agent that increases TLR2 expression when administered without a TLR2 antagonist, wherein the TLR2 antagonistic antibody or antigen binding fragment comprises a heavy chain variable region comprising a complementarity determining region (CDR) 1 region comprising the amino acid sequence of SEQ ID NO:3, a CDR2 region comprising the amino acid sequence of SEQ ID NO:4 and a CDR3 region comprising the amino acid sequence of SEQ ID NO:5, and/or a light chain variable region comprising a CDR1 region comprising the amino acid sequence of SEQ ID NO:6, a CDR2 region comprising the amino acid sequence Gly-Ala-Ser and a CDR3 region comprising the amino acid sequence of SEQ ID NO:7.
A screening method for the identification of antibodies or antigen binding fragments thereof for use in treatment or prevention of pancreatic cancer, the method comprising the steps of:
- (a) providing candidate antibodies or antigen binding fragments thereof having binding specificity for TLR2;
- (b) contacting the candidate antibodies or antigen binding fragments thereof with TLR2;
- and
- (c) identifying antibodies or antigen binding fragments thereof which antagonise TLR2 function;
- wherein antagonism of TLR2 function is indicative of utility of the antibody or antigen binding fragment thereof in the treatment or prevention of pancreatic cancer.
A screening method for the identification of secondary therapeutic compounds for use with an antagonistic TLR2 antibody or antigen binding fragment thereof in treatment or prevention of pancreatic cancer, the method comprising the steps of:
- (a) screening chemotherapeutic agents for their ability to increase TLR2 expression when administered without a TLR2 antagonist;
- wherein an increase in TLR2 expression is indicative of utility of the compound as a secondary therapeutic compound for use with an antagonistic TLR2 antibody or antigen binding fragment thereof in treatment or prevention of pancreatic cancer.
Dependencies are inferred from the claim text.